EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

Author： Freudlsperger Christian   Burnett Jeffrey R   Friedman Jay A   Kannabiran Vishnu R   Chen Zhong   Van Waes Carter  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.1, 2011-01, pp. : 63-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling

By  

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 188-204

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies

By Barrett David   Brown Valerie I.   Grupp Stephan A.   Teachey David T.  

Pediatric Drugs, Vol. 14, Iss. 5, 2012-10 ,pp. : 299-316

Adis International

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

By Martelli Alberto M   Evangelisti Camilla   Chiarini Francesca   Grimaldi Cecilia   Manzoli Lucia   McCubrey James A  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1333-1349

Informa Healthcare

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

By  

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-05 ,pp. : 36-62

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite